<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898208</url>
  </required_header>
  <id_info>
    <org_study_id>11-006920</org_study_id>
    <secondary_id>UM1AI104681</secondary_id>
    <secondary_id>KL2TR000136</secondary_id>
    <nct_id>NCT01898208</nct_id>
  </id_info>
  <brief_title>Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures</brief_title>
  <official_title>Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Would rapid identification of bacteria and rapid detection of methicillin-resistant S. aureus
      (MRSA) and vancomycin-resistant enterococci (VRE) (using an FDA-cleared assay) in positive
      blood culture bottles improve patient care at Mayo Clinic Rochester (or just lead to
      increased cost)?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that the FilmArray Blood Culture ID Panel will reduce the duration of empiric
      broad-spectrum antimicrobial therapy typically administered in patients who have positive
      blood cultures, improving clinical outcome and reducing cost. To test this hypothesis we
      propose a prospective, randomized controlled study comparing outcomes among patients with
      positive blood cultures who receive either: Standard culture and antimicrobial susceptibility
      testing (AST) of positive blood culture bottles as is done today (control), standard culture
      and AST of positive blood culture bottles plus the FilmArray Blood Culture ID Panel
      (intervention group 1), or standard culture and AST of positive blood culture bottles plus
      the FilmArray Blood Culture ID Panel testing along with expert infectious diseases phone
      consultation (intervention group 2). In both intervention groups, results of the FilmArray
      test will be communicated by phone to the primary service, along with templated comments
      about optimal antimicrobial therapy, based on the result. (Templated comments will also be
      used in the control group). In intervention group 2, an infectious diseases pharmacist or
      physician will provide patient-specific recommendations to modify antimicrobial therapy, if
      appropriate, based on microbiology results and clinical information obtained through medical
      record review and discussion with the primary service.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Antimicrobial Therapy (Hours)</measure>
    <time_frame>Approximately 4 days after enrollment</time_frame>
    <description>Difference between the date and time of the antibiotic start order (or Gram stain-positive blood culture, if antibiotics were started prior to the positive culture result) and the date and time of the antibiotic stop order. Shorter duration of broad spectrum antibiotics and longer duration of narrow-spectrum antibiotics were considered favorable outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Positive Gram Stain to First Active Antibiotic</measure>
    <time_frame>Approximately 14 days after positive blood culture</time_frame>
    <description>From positive Gram stain to start of active antibiotic among patients not on active therapy at enrollment; excludes subjects with contaminated blood cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Appropriate De-escalation or First Appropriate Escalation of Antibiotics</measure>
    <time_frame>Positive Gram stain, 96 hours after enrollment</time_frame>
    <description>De-escalation included discontinuation of 1 or more antibiotics and/or switching from a broad- to a narrow spectrum antibiotic. Escalation included initiation of 1 or more antibiotics and/or switching from a narrow- to a broad-spectrum antibiotic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Contaminated Blood Cultures Not Treated or Treated for Less Than 24 Hours</measure>
    <time_frame>Within 14 days after positive blood culture</time_frame>
    <description>Contaminated blood cultures were defined as growth of organisms such as coagulase-negative staphylococci from a single blood culture set when greater than or equal to 2 blood culture sets were collected, except among subjects suspected to have true bacteremia associated with central venous catheters or devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pathogen Identification</measure>
    <time_frame>Approximately 14 days after positive blood culture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Had Negative Blood Cultures Within 3 Days After Enrollment</measure>
    <time_frame>3 Days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Entire Hospitalization (Days)</measure>
    <time_frame>Participants were followed for the duration of hospital stay, approximately 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and Attributable Mortality</measure>
    <time_frame>30 days after positive blood culture</time_frame>
    <description>If records of death were incomplete, mortality was determined using Accurint (LexisNexis, Philadelphia, PA), an internet research and location service.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibiotic-Associated Toxicities/Adverse Events</measure>
    <time_frame>Approximately 14 days after positive blood culture</time_frame>
    <description>This included all adverse events that occurred within 2 weeks following enrollment and were documented in the medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Infectious Disease Consultation Within 72 Hours of Enrollment</measure>
    <time_frame>Approximately within 72 hours of positive blood culture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Hospitalization, Laboratory Test, and Antimicrobials Costs Per Subject</measure>
    <time_frame>Approximately 7 days after positive blood culture and for duration of entire hospitalization</time_frame>
    <description>Costs were calculated using a standardized inflation-adjusted estimate of costs for each service or procedure performed in constant dollars. This approach adjusts for hospital-billed charges with Medicare Cost Report department-level cost-to-charge ratios. Physician services were proxied with Medicare reimbursement rates based on Current Procedure Terminology (CPT)-4 codes using the Medicare Fee Schedule. We did not include the cost of the stewardship program in the cost analysis, as it is not a billed service. As there was no Medicare reimbursement rate for the rmPCR test at the time of the study, test cost was proxied using the FilmArray respiratory panel. These costs were varied in sensitivity analysis with rmPCR test cost ranging from a 50% decrease to a 300% increase.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Intensive Care Unit Stay</measure>
    <time_frame>within 14 days of positive blood culture until ICU discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patients Who Acquired Clostridium Difficile or Multidrug-resistant Organisms Within 30 Days After Enrollment</measure>
    <time_frame>Approximately 30 days after positive blood culture</time_frame>
    <description>Multidrug-resistant organisms included vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, extended-spectrum cephalosporin-resistant Enterobacteriaceae, and Pseudomonas aeruginosa and Acinetobacter species resistant to greater than or equal to 3 antibiotic classes.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">743</enrollment>
  <condition>Bacteremia</condition>
  <condition>Fungemia</condition>
  <condition>Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FilmArray test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FilmArray plus antimicrobial stewardship</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FilmArray testing</intervention_name>
    <description>FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.</description>
    <arm_group_label>FilmArray test</arm_group_label>
    <arm_group_label>FilmArray plus antimicrobial stewardship</arm_group_label>
    <other_name>FilmArray Blood Culture Identification Panel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Antimicrobial Stewardship</intervention_name>
    <description>Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.</description>
    <arm_group_label>FilmArray plus antimicrobial stewardship</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bacterial culture</intervention_name>
    <description>This test identifies the pathogen responsible for an infection.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>FilmArray test</arm_group_label>
    <arm_group_label>FilmArray plus antimicrobial stewardship</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Susceptibility testing</intervention_name>
    <description>Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>FilmArray test</arm_group_label>
    <arm_group_label>FilmArray plus antimicrobial stewardship</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Positive blood culture during the study period.

          -  No positive blood cultures in prior 7 days

          -  Minnesota state research authorization provided

        Exclusion criteria:

          -  No Minnesota state research authorization

          -  Deceased or transitioned to comfort care within 24 hours of enrollment

          -  Positive blood culture in prior 7 days

          -  Previously enrolled in this study

          -  Negative Gram stain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ritu Banerjee, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015 Oct 1;61(7):1071-80. doi: 10.1093/cid/civ447. Epub 2015 Jul 20.</citation>
    <PMID>26197846</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>December 2, 2015</results_first_submitted>
  <results_first_submitted_qc>February 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2016</results_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ritu Banerjee, M.D., Ph.D.</investigator_full_name>
    <investigator_title>MD, Ph.D</investigator_title>
  </responsible_party>
  <keyword>Bacteremia</keyword>
  <keyword>Fungemia</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>susceptibility</keyword>
  <keyword>MRSA</keyword>
  <keyword>VRE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Fungemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the Mayo Clinic in Rochester, Minnesota from August 2013 to March 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
        </group>
        <group group_id="P2">
          <title>FilmArray Test</title>
          <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture Infectious Disease (ID) Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
        </group>
        <group group_id="P3">
          <title>FilmArray Plus Antimicrobial Stewardship</title>
          <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="247"/>
                <participants group_id="P3" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Positive blood culture</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death/comfort care within 24 hours</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Negative Gram Stain</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Blood Specimens in Bottles</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>System/Technical Error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized subjects were excluded if they had a positive blood culture in the prior week, had not provided the state research authorization, previously enrolled in the study, died or transitioned to comfort care within 24 hours of enrollment, or had a negative Gram stain. Only non-excluded subjects were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
        </group>
        <group group_id="B2">
          <title>FilmArray Test</title>
          <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
        </group>
        <group group_id="B3">
          <title>FilmArray Plus Antimicrobial Stewardship</title>
          <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="212"/>
            <count group_id="B4" value="617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="19.32"/>
                    <measurement group_id="B2" value="61.4" spread="21.22"/>
                    <measurement group_id="B3" value="61.2" spread="20.08"/>
                    <measurement group_id="B4" value="61.4" spread="20.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Antimicrobial Therapy (Hours)</title>
        <description>Difference between the date and time of the antibiotic start order (or Gram stain-positive blood culture, if antibiotics were started prior to the positive culture result) and the date and time of the antibiotic stop order. Shorter duration of broad spectrum antibiotics and longer duration of narrow-spectrum antibiotics were considered favorable outcomes.</description>
        <time_frame>Approximately 4 days after enrollment</time_frame>
        <population>Subjects could have received more than one antimicrobial. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship)</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Antimicrobial Therapy (Hours)</title>
          <description>Difference between the date and time of the antibiotic start order (or Gram stain-positive blood culture, if antibiotics were started prior to the positive culture result) and the date and time of the antibiotic stop order. Shorter duration of broad spectrum antibiotics and longer duration of narrow-spectrum antibiotics were considered favorable outcomes.</description>
          <population>Subjects could have received more than one antimicrobial. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vancomycin (van), all subjects (n=132, 101, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="22" upper_limit="72"/>
                    <measurement group_id="O2" value="42" lower_limit="21" upper_limit="93"/>
                    <measurement group_id="O3" value="42" lower_limit="19" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Van, organisms not requiring van (n=56, 56,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Van-susceptible enterococci (n=8, 8, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="1" upper_limit="59"/>
                    <measurement group_id="O2" value="70" lower_limit="48" upper_limit="88"/>
                    <measurement group_id="O3" value="82" lower_limit="40" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Van, Methicillin-susceptible S.aureus(n=13,13,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="20" upper_limit="53"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O3" value="8" lower_limit="0" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nafcillin, oxacillin, or cefazolin (n=20, 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="24" upper_limit="57"/>
                    <measurement group_id="O2" value="71" lower_limit="51" upper_limit="79"/>
                    <measurement group_id="O3" value="85" lower_limit="42" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Piperacillin-tazobactam (n=77, 65, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="39" upper_limit="82"/>
                    <measurement group_id="O2" value="44" lower_limit="27" upper_limit="74"/>
                    <measurement group_id="O3" value="45" lower_limit="19" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cefepime (n=62, 52, 67</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="28" upper_limit="96"/>
                    <measurement group_id="O2" value="71" lower_limit="43" upper_limit="96"/>
                    <measurement group_id="O3" value="58" lower_limit="32" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For Vancomycin, all patients</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For vancomycin, organisms not requiring vancomycin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For vancomycin-susceptible enterococci</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For vancomycin, methicillin-susceptible Staphylococcus aureus.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For nafcillin, oxacillin, or cefazolin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For piperacillin-tazobactam.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For cefepime.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Positive Gram Stain to First Active Antibiotic</title>
        <description>From positive Gram stain to start of active antibiotic among patients not on active therapy at enrollment; excludes subjects with contaminated blood cultures.</description>
        <time_frame>Approximately 14 days after positive blood culture</time_frame>
        <population>Not all subjects were not on active therapy at enrollment, and also subjects with contaminated blood cultures were excluded. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship): (n=45, 41, 37)</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Positive Gram Stain to First Active Antibiotic</title>
          <description>From positive Gram stain to start of active antibiotic among patients not on active therapy at enrollment; excludes subjects with contaminated blood cultures.</description>
          <population>Not all subjects were not on active therapy at enrollment, and also subjects with contaminated blood cultures were excluded. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship): (n=45, 41, 37)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="2" upper_limit="51"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="31"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Appropriate De-escalation or First Appropriate Escalation of Antibiotics</title>
        <description>De-escalation included discontinuation of 1 or more antibiotics and/or switching from a broad- to a narrow spectrum antibiotic. Escalation included initiation of 1 or more antibiotics and/or switching from a narrow- to a broad-spectrum antibiotic.</description>
        <time_frame>Positive Gram stain, 96 hours after enrollment</time_frame>
        <population>Not all subjects experienced de-escalation or escalation of their antibiotics. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship).</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Appropriate De-escalation or First Appropriate Escalation of Antibiotics</title>
          <description>De-escalation included discontinuation of 1 or more antibiotics and/or switching from a broad- to a narrow spectrum antibiotic. Escalation included initiation of 1 or more antibiotics and/or switching from a narrow- to a broad-spectrum antibiotic.</description>
          <population>Not all subjects experienced de-escalation or escalation of their antibiotics. Participants analyzed per variable below are expressed as (n=control, FilmArray test, and FilmArray+Stewardship).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to first approp. de-escalation(n=121,112,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="21" upper_limit="55"/>
                    <measurement group_id="O2" value="38" lower_limit="22" upper_limit="66"/>
                    <measurement group_id="O3" value="21" lower_limit="7" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to first appropriate escalation (40,38,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="3" upper_limit="67"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="36"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For time to first appropriate de-escalation comparing the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For time to first appropriate escalation comparing the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Contaminated Blood Cultures Not Treated or Treated for Less Than 24 Hours</title>
        <description>Contaminated blood cultures were defined as growth of organisms such as coagulase-negative staphylococci from a single blood culture set when greater than or equal to 2 blood culture sets were collected, except among subjects suspected to have true bacteremia associated with central venous catheters or devices.</description>
        <time_frame>Within 14 days after positive blood culture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Contaminated Blood Cultures Not Treated or Treated for Less Than 24 Hours</title>
          <description>Contaminated blood cultures were defined as growth of organisms such as coagulase-negative staphylococci from a single blood culture set when greater than or equal to 2 blood culture sets were collected, except among subjects suspected to have true bacteremia associated with central venous catheters or devices.</description>
          <units>Percentage of blood cultures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pathogen Identification</title>
        <time_frame>Approximately 14 days after positive blood culture</time_frame>
        <population>The number of subjects analyzed per arm differs from the number of subjects who completed the study because this outcome measure includes only the subset of subjects who had organisms represented on the rapid multiplex PCR (rmPCR) panel.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pathogen Identification</title>
          <population>The number of subjects analyzed per arm differs from the number of subjects who completed the study because this outcome measure includes only the subset of subjects who had organisms represented on the rapid multiplex PCR (rmPCR) panel.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17" upper_limit="28"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.9" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.9" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares the FilmArray test to control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares FilmArray plus antimicrobial stewardship to the control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Had Negative Blood Cultures Within 3 Days After Enrollment</title>
        <time_frame>3 Days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had Negative Blood Cultures Within 3 Days After Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is to compare the three groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Length of Intensive Care Unit Stay</title>
        <time_frame>within 14 days of positive blood culture until ICU discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Patients Who Acquired Clostridium Difficile or Multidrug-resistant Organisms Within 30 Days After Enrollment</title>
        <description>Multidrug-resistant organisms included vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, extended-spectrum cephalosporin-resistant Enterobacteriaceae, and Pseudomonas aeruginosa and Acinetobacter species resistant to greater than or equal to 3 antibiotic classes.</description>
        <time_frame>Approximately 30 days after positive blood culture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Acquired Clostridium Difficile or Multidrug-resistant Organisms Within 30 Days After Enrollment</title>
          <description>Multidrug-resistant organisms included vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, extended-spectrum cephalosporin-resistant Enterobacteriaceae, and Pseudomonas aeruginosa and Acinetobacter species resistant to greater than or equal to 3 antibiotic classes.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="8.1"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is a comparison of the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Entire Hospitalization (Days)</title>
        <time_frame>Participants were followed for the duration of hospital stay, approximately 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Entire Hospitalization (Days)</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="O3" value="8" lower_limit="5" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis compares the three groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause and Attributable Mortality</title>
        <description>If records of death were incomplete, mortality was determined using Accurint (LexisNexis, Philadelphia, PA), an internet research and location service.</description>
        <time_frame>30 days after positive blood culture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause and Attributable Mortality</title>
          <description>If records of death were incomplete, mortality was determined using Accurint (LexisNexis, Philadelphia, PA), an internet research and location service.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attributable mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of the 3 groups for all-cause mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of the 3 groups for attributable mortality.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibiotic-Associated Toxicities/Adverse Events</title>
        <description>This included all adverse events that occurred within 2 weeks following enrollment and were documented in the medical record.</description>
        <time_frame>Approximately 14 days after positive blood culture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibiotic-Associated Toxicities/Adverse Events</title>
          <description>This included all adverse events that occurred within 2 weeks following enrollment and were documented in the medical record.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This analysis is a comparison across all three groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Infectious Disease Consultation Within 72 Hours of Enrollment</title>
        <time_frame>Approximately within 72 hours of positive blood culture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Infectious Disease Consultation Within 72 Hours of Enrollment</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Hospitalization, Laboratory Test, and Antimicrobials Costs Per Subject</title>
        <description>Costs were calculated using a standardized inflation-adjusted estimate of costs for each service or procedure performed in constant dollars. This approach adjusts for hospital-billed charges with Medicare Cost Report department-level cost-to-charge ratios. Physician services were proxied with Medicare reimbursement rates based on Current Procedure Terminology (CPT)-4 codes using the Medicare Fee Schedule. We did not include the cost of the stewardship program in the cost analysis, as it is not a billed service. As there was no Medicare reimbursement rate for the rmPCR test at the time of the study, test cost was proxied using the FilmArray respiratory panel. These costs were varied in sensitivity analysis with rmPCR test cost ranging from a 50% decrease to a 300% increase.</description>
        <time_frame>Approximately 7 days after positive blood culture and for duration of entire hospitalization</time_frame>
        <population>The number of subjects analyzed per arm is different than the number of subjects who completed the study because outpatients and a few subjects without final billing data available were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
          </group>
          <group group_id="O2">
            <title>FilmArray Test</title>
            <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
          </group>
          <group group_id="O3">
            <title>FilmArray Plus Antimicrobial Stewardship</title>
            <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Hospitalization, Laboratory Test, and Antimicrobials Costs Per Subject</title>
          <description>Costs were calculated using a standardized inflation-adjusted estimate of costs for each service or procedure performed in constant dollars. This approach adjusts for hospital-billed charges with Medicare Cost Report department-level cost-to-charge ratios. Physician services were proxied with Medicare reimbursement rates based on Current Procedure Terminology (CPT)-4 codes using the Medicare Fee Schedule. We did not include the cost of the stewardship program in the cost analysis, as it is not a billed service. As there was no Medicare reimbursement rate for the rmPCR test at the time of the study, test cost was proxied using the FilmArray respiratory panel. These costs were varied in sensitivity analysis with rmPCR test cost ranging from a 50% decrease to a 300% increase.</description>
          <population>The number of subjects analyzed per arm is different than the number of subjects who completed the study because outpatients and a few subjects without final billing data available were excluded.</population>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Hospitalization Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65,450" spread="128,686"/>
                    <measurement group_id="O2" value="66,887" spread="117,832"/>
                    <measurement group_id="O3" value="68,729" spread="134,215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Test Cost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5,377" spread="10,115"/>
                    <measurement group_id="O2" value="5,680" spread="8,872"/>
                    <measurement group_id="O3" value="5,743" spread="9,809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antimicrobials Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,194" spread="4,175"/>
                    <measurement group_id="O2" value="1,932" spread="3,175"/>
                    <measurement group_id="O3" value="1,741" spread="2,748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison between the 3 arms for total hospitalization costs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7789</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison between the 3 arms for laboratory test cost.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison between the 3 arms for antimicrobials costs.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6540</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All events that occurred within 2 weeks following enrollment and were documented in the medical record were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Standard Mayo practices (culture and susceptibility testing) will be used. FilmArray testing will not be performed.</description>
        </group>
        <group group_id="E2">
          <title>FilmArray Test</title>
          <description>Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.</description>
        </group>
        <group group_id="E3">
          <title>FilmArray Plus Antimicrobial Stewardship</title>
          <description>Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelosuppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ritu Banerjee, M.D., Ph.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-6904</phone>
      <email>banerjee.ritu@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

